A heart-device startup braves the IPO waters
(UPDATED: See below.)
It’s been a rough few months for life-science IPOs, what with all the collapsed offerings and, often enough, miserable post-offering performance for those startups that have managed to inch their way across the finish line.
Yet the lure of the public markets remains strong, even… Continue Reading
Life sciences briefing: Thursday, Feb. 28, 2008
TODAY’S HEADLINES:
RNAi developer PhaseRx gets $4M of a pledged $19M (Seattle Times)
TyRx Pharma, drug-device combo maker, raises $25M (release)
Agennix aims at $40M for cancer drugs (VentureWire)
Starr Life Sciences goes after $1.6M for small-animal vital-signs scanner (VW)
CardioNet sets IPO terms, aims to raise $96M (IPOhome)
RNAi developer… Continue Reading
IPO status board: The good, the bad and the pending
Now that the Bioheart IPO has doubly surprised everyone — first by happening at all, and second by coming out on such dreadful terms for the company — perhaps it’s time to take a closer look at exactly where the 2008 offering market for life-science… Continue Reading
Bioheart: A new record for IPO futility?
The embattled cell-therapy startup Bioheart finally limped across the IPO goal line yesterday, but it was a Pyhrric victory. The startup, which once sought $70 million, ended up netting as little as $1.5 million. And almost half of that amount came directly from Bioheart founder… Continue Reading
Three yards and a cloud of dust: Bioheart limps across the IPO goal line, but with little to show for its struggles
The New York Giants they ain’t, but the team at embattled cell-therapy startup Bioheart still managed to defy long odds and successfully dragged their company into the IPO endzone earlier today. No doubt football great Dan Marino — one of the Sunrise, Fla., biotech’s backers… Continue Reading
Life sciences briefing: Friday, Feb. 15, 2008
TODAY’S HEADLINES:
Q Thera takes in $15M for neural stem-cell treatments (release)
Stroke clotbuster Concentric Medical withdraws IPO (IPOhome)
Avera recaps with $9M to relaunch human tests of GI drug (VentureWire)
Tissue repairer Nerites raises $5.7M (release)
Semafore Pharma aims for $7.5M to launch new cancer-drug trials (VentureWire)
Triage Wireless gets… Continue Reading
Life sciences briefing: Thursday, Feb. 14, 2008
TODAY’S HEADLINES:
Arbor Surgical draws another $5.5M for heart-valve replacements (VBLS exclusive)
AstraZeneca spinout Albireo raises $27M for GI drugs (release)
Knee-implant maker MAKO Surgical slashes IPO price range (release)
eScreen takes in $8M for automated drug screening (peHUB)
GlucoLight gets undisclosed funding for glucose monitoring (release)
Oddo et al. order… Continue Reading
Levitation option still valid for Wile E. Coyote
Fresh from the Department of Whistling Past the Graveyard in today’s VentureWire:
Back in the real world, seven life-science IPOs have gone down in flames so far this year. An eighth startup, robotic-surgery maker MAKO Surgical, just slashed its offering price.
Life-science IPOs hit the skids
Last year was a tough one for IPOs, as Matt noted earlier, and so far this year looks even worse. Aptamer-drug maker Archemix today became the third life-science startup this month to withdraw or postpone an IPO, and the sixth so far this year. We… Continue Reading
IPO roundup: Is the window slamming on life sciences?
It’s sure starting to look that way. News that Archemix, a Cambridge, Mass., developer of aptamer-based drugs, yesterday withdrew its $72.5 million IPO follows closely on the heels of several other recent several other IPO collapses, including those of implantable diagnostic maker Transoma Medical and… Continue Reading
Life sciences briefing: Monday, Feb. 4, 2008
TODAY’S HEADLINES:
PEAK Surgical takes in $21M for electrosurgical tools (release)
CellGate acquired by Australian cancer biotech ProGen for $2.5M (release)
Traversa raises $2M for RNAi-delivery technologies (release)
RemitDATA, Web-based healthcare-service co., takes in $5.5M (bizjournals.com)
Spinal-implant maker Archus Orthopedics gets $10M venture loan (release)
Promedior pulls down another $5.5M for… Continue Reading
Life sciences briefing: Friday, Feb. 1, 2008
TODAY’S HEADLINES:
Taligen Therapeutics raises $65M for novel anti-inflammatory drugs (release)
Dental-implant maker Biohorizons acquires Implant Logic (release)
MAKO Surgical sets IPO terms, seeks $94M for knee implants and robots (Edgar)
Canada’s Medical Ventures acquires two Israeli device startups (release)
CRO Chiltern acquires Drug Development Solutions (release)
Taligen Therapeutics raises $65M… Continue Reading
Life sciences briefing: Friday, Jan. 25, 2008
TODAY’S HEADLINES:
Health-info site HealthCentral Network pulls in $50M (paidContent)
BrightHeart Vet corrals $29M to acquire animal hospitals (release)
AviaraDx raises $8M for cancer diagnostics (peHUB)
Valor Medical aims for $15M for brain-aneurysm treatment (VentureWire)
IPC, inpatient-care provider, raises as much as $56M in IPO (IPO Home)
Phenomix, diabetes and hepatitis… Continue Reading
Life sciences briefing: Wednesday, Jan. 23, 2008
TODAY’S HEADLINES:
Mauna Kea Tech raises $30M for in-vivo cellular imaging (release)
Knopp Neuro takes in $10M for Lou Gehrig’s drug (release)
Cardiovascular Systems, arterial-plaque device maker, files for $86M IPO (Edgar)
Diagnostics maker BG Medicine withdraws IPO (release)
Signature Genomics Labs sells stake to Ampersand Ventures (release)
Cambridge Temp raises… Continue Reading
Life sciences briefing: Friday, Jan. 18, 2007
TODAY’S HEADLINES:
Ulthera receives $23M for cosmetic ultrasound devices (release)
Senexis raises £2.9M for Alzheimer’s drugs (PDF release)
Elixir Pharma postpones IPO (IPO Home)
Cancer Therapeutics names Randall Riggs as CEO (release)
Ulthera receives $23M for cosmetic ultrasound devices — Ulthera, a Mesa, Ariz., startup developing ultrasound systems for cosmetic… Continue Reading
Life sciences briefing: Thursday, Jan. 17, 2007
TODAY’S HEADLINES:
TransEnterix gets $21M for minimally invasive GI surgery (release)
Stem-cell developer Bioheart’s IPO postponed (Forbes.com)
Medical-practice software provider AdvancedMD acquired by Francisco Partners (release)
Peptimmune draws $8.2M for MS drug trials (release)
Drug-delivery co. Talima Thera names Martin Babler CEO (release)
Alimera Sciences aims for autumn IPO to fund… Continue Reading
Life sciences briefing: Wednesday, Jan. 16, 2008
TODAY’S HEADLINES:
Drug-screening tool maker IonGate Bio raises €4.6M (release)
Protein-drug maker Molecular Partners gets $5M up front in Centocor deal (PDF release)
ProtaGen takes in €1M for protein biochips (PDF release)
China’s Sundia MediTech, a contract research organization raises second round (release)
Vital-signs implant maker Transoma Medical sets IPO… Continue Reading
Life sciences briefing: Wednesday, Jan. 2, 2008
TODAY’S HEADLINES:
Israel’s Alma Lasers files for $86M IPO (Edgar)
Allscripts acquires hospital-management software co. ECIN for $90M (release)
AgaMatrix, glucose-sensor maker, raises $24M (PE Hub)
Israel’s Alma Lasers files for $86M IPO — Alma Lasers, an Israeli maker of lasers for cosmetic procedures, filed to raise $86.3 million… Continue Reading
The storm over stents hits venture firms, as Devax yanks $85M IPO filing
Devax, a Lake Forest, Calif., maker of artery-opening stents, withdrew its filing for an IPO that the company estimated would raise $85 million. The company filed for its IPO in May, but until its withdrawal hadn’t filed any revisions to that preliminary document since.
The withdrawal… Continue Reading
Life sciences briefing: Thursday, Dec. 6, 2007
(UPDATED: Expanded items on LineaGen, BG Medicine. Pelikan Tech is described in a standalone item here.)
TODAY’S HEADLINES:
Pelikan Tech raises $69M for diabetes glucose tests (release)
Utah’s LineaGen draws $6M for genetic diagnostics (VentureWire, sub req’d)
Beijing’s IKang Healthcare gets $25M for medical-service centers (VW)
BG Medicine drops IPO price… Continue Reading